Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Post by cacfacmaon Feb 23, 2024 8:20am
172 Views
Post# 35895138

yesterday's call

yesterday's callIn my opinion, Baxter does not want Spectral price to pop prior to its IPO of Vantive and is calling the shots.  Why would we expect otherwise?  Baxter is the big whale, Spectral is the little fish. 

I do not believe there is any statistical hit associated with releasing crude mortality results at 90 patients.   Clearly, if this was the case, Spectral would not have gone on record a year ago that they would release these interim results.  

We should all be reviewing analyst reports from Baxter to pick up on any reference to upcoming Vantive IPO and related details on PMX/EAA.


<< Previous
Bullboard Posts
Next >>